AstraZeneca Announces Plans to Expand its Frederick, Maryland Biologics Manufacturing Center

SourceMarket Watch
Date Published11/21/2014
Author NameAlisha Martin
Mentions specific company case(s) of reshoring, kept from offshoring, or transplantYes

Additional Reshoring Information:

Company/Division name AstraZeneca
Type of work Manufacturing
If manufacturing, is the company an OEM? Yes
Reshoring category:Transplant
Total number of jobs (added or to be added):300
Year reshoring announced:2014
Year reshoring implemented or to be implemented:2014
Domestically, the work will be done:In-house
Capital investment ($):200
Country(ies) from which reshored:United Kingdom
City reshored to:Frederick
State(s) reshored to:MD
If relevant, work nearshored to:-
Industry(ies):Medical Equipment/Supplies, Other
Product(s) reshoredPharmaceuticals
What domestic positive factors made reshoring more attractive?Eco-system synergies, Skilled workforce availability/training, growing biotech community
Find Reshoring Articles